Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.

EW, Ely; PF, Laterre; DC, Angus; JD, Helterbrand; H, Levy; JF, Dhainaut; JL, Vincent; WL, Macias; GR, Bernard

doi:10.1097/00003246-200301000-00002

Public

Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.

Shared by NobleBlocks on Jan 1, 2003 • 12:00 AM UTC

Authors:

Ely EW

Laterre PF

Angus DC

Abstract

<h4>Objective</h4>To assess the effects of drotrecogin alfa (activated) therapy, a recombinant human activated protein C, across clinically relevant subpopulations in a randomized, phase 3, placebo-controlled study of patients with severe sepsis (recombinant human activated protein C worldwide evalu...

Discussions